Literature DB >> 22238327

Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.

Shinsuke Hirabayashi1, Christian Flotho, Jessica Moetter, Michael Heuser, Henrik Hasle, Bernd Gruhn, Thomas Klingebiel, Felicitas Thol, Brigitte Schlegelberger, Irith Baumann, Brigitte Strahm, Jan Stary, Franco Locatelli, Marco Zecca, Eva Bergstraesser, Michael Dworzak, Marry M van den Heuvel-Eibrink, Barbara De Moerloose, Seishi Ogawa, Charlotte M Niemeyer, Marcin W Wlodarski.   

Abstract

Somatic mutations of the spliceosomal machinery occur frequently in adult patients with myelodysplastic syndrome (MDS). We resequenced SF3B1, U2AF35, and SRSF2 in 371 children with MDS or juvenile myelomonocytic leukemia. We found missense mutations in 2 juvenile myelomonocytic leukemia cases and in 1 child with systemic mastocytosis with MDS. In 1 juvenile myelomonocytic leukemia patient, the SRSF2 mutation that initially coexisted with an oncogenic NRAS mutation was absent at relapse, whereas the NRAS mutation persisted and a second, concomitant NRAS mutation later emerged. The patient with systemic mastocytosis and MDS carried both mutated U2AF35 and KIT in a single clone as confirmed by clonal sequencing. In the adult MDS patients sequenced for control purposes, we detected previously reported mutations in 7/30 and a novel SRSF2 deletion (c.284_307del) in 3 of 30 patients. These findings implicate that spliceosome mutations are rare in pediatric MDS and juvenile myelomonocytic leukemia and are unlikely to operate as driver mutations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22238327     DOI: 10.1182/blood-2011-12-395087

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia.

Authors:  Sarah Abu Kar; Anna Jankowska; Hideki Makishima; Valeria Visconte; Andres Jerez; Yuka Sugimoto; Hideki Muramatsu; Fabiola Traina; Manuel Afable; Kathryn Guinta; Ramon V Tiu; Bartlomiej Przychodzen; Hirotoshi Sakaguchi; Seiji Kojima; Mikkael A Sekeres; Alan F List; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

Review 2.  Defects in spliceosomal machinery: a new pathway of leukaemogenesis.

Authors:  Jaroslaw P Maciejewski; Richard A Padgett
Journal:  Br J Haematol       Date:  2012-05-18       Impact factor: 6.998

Review 3.  Pre-mRNA splicing in disease and therapeutics.

Authors:  Ravi K Singh; Thomas A Cooper
Journal:  Trends Mol Med       Date:  2012-07-18       Impact factor: 11.951

4.  Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients.

Authors:  Siobán B Keel; Angela Scott; Marilyn Sanchez-Bonilla; Phoenix A Ho; Suleyman Gulsuner; Colin C Pritchard; Janis L Abkowitz; Mary-Claire King; Tom Walsh; Akiko Shimamura
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

5.  Mutational analysis of RNA splicing machinery components in 206 children with myeloid malignancies.

Authors:  Hirotoshi Sakaguchi; Hideki Makishima; Hideki Muramatsu; Valeria Visconte; Andres Jerez; Anna M Jankowska; Ramon V Tiu; Jaroslaw P Maciejewski; Seiji Kojima
Journal:  Leuk Res       Date:  2012-06-28       Impact factor: 3.156

6.  Lack of splice factor and cohesin complex mutations in pediatric myelodysplastic syndrome.

Authors:  Julia C Obenauer; François G Kavelaars; Mathijs A Sanders; Remco M Hoogenboezem; Andrica C H de Vries; Paulina M H van Strien; Valerie de Haas; Franco Locatelli; Henrik Hasle; Peter J M Valk; Ivo P Touw; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2016-09-01       Impact factor: 9.941

Review 7.  Splicing factor mutations in myelodysplasia.

Authors:  Seishi Ogawa
Journal:  Int J Hematol       Date:  2012-10-05       Impact factor: 2.490

Review 8.  The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression.

Authors:  Asaf Shilo; Zahava Siegfried; Rotem Karni
Journal:  Mol Cell Oncol       Date:  2014-12-01

9.  SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing.

Authors:  Yukiko Komeno; Yi-Jou Huang; Jinsong Qiu; Leo Lin; YiJun Xu; Yu Zhou; Liang Chen; Dora D Monterroza; Hairi Li; Russell C DeKelver; Ming Yan; Xiang-Dong Fu; Dong-Er Zhang
Journal:  Mol Cell Biol       Date:  2015-06-29       Impact factor: 4.272

Review 10.  The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.

Authors:  Thomas R Webb; Amanda S Joyner; Philip M Potter
Journal:  Drug Discov Today       Date:  2012-08-03       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.